Market Presence NeuroPace has a strong market presence in the medical equipment manufacturing industry, with its innovative RNS System being the world's first and only medical device that can monitor and respond to brain activity. This uniqueness can be leveraged to target customers seeking cutting-edge solutions for neurological disorders.

Upcoming Events With scheduled presentations at prestigious healthcare conferences like the J.P. Morgan Healthcare Conference and hosting an Investor Day in New York City, NeuroPace is actively engaging with potential investors and industry professionals. These events provide opportunities to showcase the benefits of the RNS System to a wide audience.

Positive Analyst Sentiment Wall Street analysts have shown optimism towards NeuroPace, predicting potential stock upside ranging from 31.5% to 54.3%. This positive sentiment can be utilized to attract investors looking for growth opportunities in the medical device sector, positioning NeuroPace as an appealing investment prospect.

Scientific Presentations NeuroPace is actively participating in scientific conferences like the American Epilepsy Society Annual Meeting to showcase the RNS System's latest innovations. Engaging with key opinion leaders and demonstrating the system's advancements can create sales opportunities by solidifying NeuroPace's position as a leader in epilepsy treatment.

Feasibility Study Completion The completion of the feasibility study of the RNS System for Lennox-Gastaut Syndrome, a severe childhood-onset epilepsy, demonstrates NeuroPace's commitment to expanding the applications of its technology. This milestone can be highlighted to engage with healthcare institutions and physicians interested in adopting innovative therapies for epilepsy management.